Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Poor Quality Data On Immune-Related Adverse Events Slowed Yervoy Review

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Questions surrounding immune-mediated adverse events with Bristol-Myers Squibb’s Yervoy (ipilimumab) and how these risks should be conveyed to practitioners proved problematic in FDA’s review of the breakthrough treatment for metastatic melanoma, leading to a three-month delay in approval.

You may also be interested in...

Bristol Expands Immunotherapy Footprint With Anti-PD-1

In a Phase I trial reported at ASCO, BMS’ new immunotherapeutic antibody BMS-936558 had impressive results against melanoma, renal cell cancer and non-small cell lung cancer, including the intractable squamous cell variety. The company is already testing it in combination with Yervoy to “move melanoma treatment to new heights.”

Review Of Reviews: Drug Review Profiles Of 2011

Each month, Pharmaceutical Approvals Monthly analyzes the FDA review process for a recent approval based on the NDA or BLA review documents. A detailed chronology of product development and listing of key reviewers accompany each profile.

Yervoy Survival Data From First-Line Study Sealed The Deal For FDA Approval

FDA’s approval of Bristol-Myers Squibb’s metastatic melanoma immunotherapy was granted only after looking outside the BLA for assurance that the biologic’s effect was robust and validated.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts